Liver Function Assessment in Oncology Practice

Czech version

Authors: J. Tomášek ¹; J. Prášek ²; I. Kiss ¹; L. Husová ³; J. Podhorec ¹
Authors‘ workplace: Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno ¹; Klinika Nukleární mediciny FN Brno ²; Centrum kardiovaskulární a transplantační chirurgie FN u sv. Anny v Brně ³
Published in: Klin Onkol 2012; 25(6): 427-433
Category: Reviews

Práce byla podpořena grantem GA ČR č. NT/11128-4/2010, „Endoluminální radiofrekvenční ablace tumorů postihujících žlučové cesty“.

Autoři deklarují, že v souvislosti s předmětem studie nemají žádné komerční zájmy.

Redakční rada potvrzuje, že rukopis práce splnil ICMJE kritéria pro publikace zasílané do bi omedicínských časopisů.

Overview

The overall condition and prognosis of a patient can be affected by impaired liver function. It applies to anticancer pharmacotherapy, liver surgery and radiological interventions. The liver condition is usually assessed by common laboratory tests and clinical examination in daily practice. Liver tests consist of aminotransferases – alanine transaminase, aspartate transaminase, bilirubin, alkaline phosphatase, gamma glutamyl transpeptidase, lactate dehydrogenase, albumin and prothrombin time, less frequently prealbumin and cholinesterase. The alkaline phosphatase and aspartate transaminase are markers of a liver damage, the alkaline phosphatase and gamma glutamyl transpeptidase are most useful as markers for cholestatic liver injury. Albumin, prealbumin, cholinesterase and prothrombin time are the markers of synthetic liver function. Bilirubin and bile acids are related to the liver transport and excretory capacity. The Child-Pugh score is used to assess prognosis of chronic liver disease, mainly cirrhosis. The examination of liver function using indocyanine green helps to determinate the extent of possible liver resection. A mathematical analysis of dynamic cholescintigraphy and a calculation of hepatic extraction fraction enables quantification of liver function. Other liver function tests are of little use in oncology.

Key words:
liver function tests – drug induced liver injury – indocyanine green – nuclear medicine

Sources

1. Racanelli V, Rehermann B. The liver as an immunological organ. Hepatology 2006; 43 (2 Suppl 1): S54–S62.

2. Červinková Z. Funkce jater. In: Ehrmann J, Hůlek P (eds). Hepatologie. Praha: Grada 2010: 25–36.

3. Vítek L. Laboratorní vyšetřovací metody. In: Ehrmann J, Hůlek P (eds). Hepatologie. Praha: Grada 2010: 42–52.

4. CTCAE verze 4.0. National Cancer Institute. Available from: http://ctep.cancer.gov/protocolDevelopment//electronic_applications/ctc.htm#ctc_40.

5. Child CG, Turcotte JG. Surgery and portal hypertension. In: Child CG (ed). The liver and portal hypertension. Philadelphia: Saunders 1964: 50–62.

6. Kamath PS, Wiesner RH, Malinchoc M et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33(2): 464–470.

7. Carithers RL Jr. Liver transplantation. American Association for the Study of Liver Diseases. Liver Transpl 2000; 6(1): 122–135.

8. United Network For Organ Sharing, Richmond, USA, MELD, PELD kalkulator. Available from: http://www.unos.org/docs/MELD_PELD_Calculator_Documentation.pdf.

9. Wiesner RH, McDiarmid SV, Kamath PS et al. MELD and PELD: application of survival models to liver allocation. Liver Transpl 2001; 7(7): 567–580.

10. Stremmel W, Wojdat R, Groteguth R et al. Liver function tests in a clinical comparison. Z Gastroenterol 1992; 30(11): 784–790.

11. Sakka SG, Reinhart K, Meier-Hellmann A. Prognostic value of the indocyanine green plasma disappearance rate in critically ill patients. Chest 2002; 122(5): 1715–1720.

12. Tsubono T, Todo S, Jabbour N et al. Indocyanine green elimination test in orthotopic liver recipients. Hepatology 1996; 24(5): 1165–1171.

13. Plevris JN, Jalan R, Bzeizi KI et al. Indocyanine green clearance reflects reperfusion injury following liver transplantation and is an early predictor of graft function. J Hepatol 1999; 30(1): 142–148.

14. Faybik P, Krenn CG, Baker A et al. Comparison of invasive and noninvasive measurement of plasma disappearance rate of indocyanine green in patients undergoing liver transplantation: a prospective investigator-blinded study. Liver Transpl 2004; 10(8): 1060–1064.

15. Purcell R, Kruger P, Jones M. Indocyanine green elimination: a comparison of the LiMON and serial blood sampling methods. ANZ J Surg 2006; 76(1–2): 75–77.

16. Sakka SG. Assessing liver function. Curr Opin Crit Care 2007; 13(2): 207–214.

17. Leypold J, Kriz Z, Privara M et al. Vyšetření funkční zdatnosti jaterního parenchymu s pomocí indocyaninové zeleně před resekcí jater. Bratisl Lek Listy 2001; 102(2): 115–116.

18. Miyagawa S, Makuuchi M, Kawasaki S et al. Criteria for safe hepatic resection. Am J Surg 1995; 169(6): 589–594.

19. Lee SG, Hwang S. How I do it: assessment of hepatic reserve for indication of hepatic resection. J Hepatobiliary Pancreat Surg 2005; 12(1): 38–43.

20. Lodge JP. Assessment of hepatic reserve for the indication of hepatic resection: how I do it. J Hepatobiliary Pancreat Surg 2005; 12(1): 4–9.

21. Krishnamurthy S, Krishnamurthy GT. Quantitative assessment of hepatobiliary diseases with Tc99m-IDA scintigraphy. In: Freeman LM (ed). Nuclear medicine annual. New York: Raven Press 1988: 309–330.

22. Prášek J. Atlas of dynamic cholescintigraphy. Praha: Lacomed 2004.

23. Tagge EP, Campbell DA Jr, Reichle R et al. Quantitative scintigraphy with deconvolutional analysis for the dynamic measurement of hepatic function. J Surg Res 1987; 42(6): 605–612.

24. Prasek J, Hep A, Dite P et al. The influence of dicetel on the mean transit time of 99mTc Trimethyl HIDA. Hepatogastroenterology 1994; 41(3): 302.

25. Jalan R, Hayes PC. Review article: quantitative tests of liver function. Aliment Pharmacol Ther 1995; 9(3): 263–270.

26. Reichen J. Assessment of hepatic function with xenobiotics. Semin Liver Dis 1995; 15(3): 189–201.

27. Kysela P. Způsoby vyšetření funkčních rezerv jaterního parenchymu. In: Válek V, Kala Z, Kiss I (eds). Maligní ložiskové procesy jater, diagnostika a léčba včetně minimálně invazivních metod. Praha: Grada 2006: 244–247.

28. Urbain D, Muls V, Thys O et al. Aminopyrine breath test improves long-term prognostic evaluation in patients with alcoholic cirrhosis Child classes A and B. J Hepatol 1995; 22(2): 179–183.

29. Horák J. Kvantifikace jaterních funkcí. In: Ehrmann J, Hůlek P (eds). Hepatologie. Praha: Grada 2010: 52–56.

30. Červinková Z, Šoerl J. Toxické poškození jater. In: Ehrmann J, Hůlek P (eds). Hepatologie. Praha: Grada 2010: 365–371.

31. Avilés A, Herrera J, Ramos E et al. Hepatic injury during doxorubicin therapy. Arch Pathol Lab Med 1984; 108(11): 912–913.

32. Carreras E. Veno-occlusive disease of the liver after hemopoietic cell transplantation. Eur J Haematol 2000; 64(5): 281–291.

33. Tran A, Housset C, Boboc B et al. Etoposide (VP 16-213) induced hepatitis. Report of three cases following standard-dose treatments. J Hepatol 1991; 12(1): 36–39.

34. Hill JM, Loeb E, MacLellan A et al. Clinical studies of platinum coordination compounds in the treatment of various malignant diseases. Cancer Chemother Rep 1975; 59(3): 647–659.

35. Asbury RF, Rosenthal SN, Descalzi ME et al. Hepatic veno-occlusive disease due to DTIC. Cancer 1980; 45(10): 2670–2674.

36. Moertel CG, Fleming TR, Macdonald JS et al. Hepatic toxicity associated with fluorouracil plus levamisole adjutant therapy. J Clin Oncol 1993; 11(12): 2386–2390.

37. Peppercorn PD, Reznek RH, Wilson P et al. Demonstration of hepatic steatosis by computerized tomography in patients receiving 5-fluorouracil-based therapy for advanced colorectal cancer. Br J Cancer 1998; 77(11): 2008–2011.

38. Saif MW, Shahrokni A, Cornfeld D. Gemcitabine-induced liver fibrosis in a patient with pancreatic cancer. JOP 2007; 8(4): 460–467.

39. Morris-Stiff G, Tan YM, Vauthey JN. Hepatic complications following preoperative chemotherapy with oxaliplatin or irinotecan for hepatic colorectal metastases. Eur J Surg Oncol 2008; 34(6): 609–614.

40. Scheithauer W, McKendrick J, Begbie S et al. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol 2003; 14(12): 1735–1743.

41. Van Cutsem E, Twelves C, Cassidy J et al. Oral capecitabin compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001; 19(21): 4097–4106.

42. Lazarus HM, Herzig RH, Graham-Pole J et al. Intensive melphalan chemotherapy and cryopreserved autologous bone marrow transplantation for the treatment of refractory cancer. J Clin Oncol 1983; 1(6): 359–367.

43. Hoekstra M, van Ede AE, Haagsma C et al. Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis. Ann Rheum Dis 2003; 62(5): 423–426.

44. Vauthey JN, Pawlik TM, Ribero D et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006; 24(13): 2065–2072.

45. Morris-Stiff G, Tan YM, Vauthey JN. Hepatic complications following preoperative chemotherapy with oxaliplatin or irinotecan for hepatic colorectal metastases. Eur J Surg Oncol 2008; 34(6): 609–614.

46. Huizing MT, Misser VH, Pieters RC et al. Taxanes: a new class of antitumor agents. Cancer Invest 1995; 13(4): 381–404.

47. Creemers GJ, Lund B, Verweij J. Topoisomerase I inhibitors: topotecan and irinotecan. Cancer Treat Rev 1994; 20(1): 73–96.

48. Quesada JR, Talpaz M, Rios A et al. Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol 1986; 4(2): 234–243.

49. Scarpignato C, Pelosini I. Somatostatin analogs for cancer treatment and diagnosis: an overview. Chemotherapy 2001; 47 (Suppl 2): 1–29.

50. Ho C, Davis J, Anderson F et al. Side effects related to cancer treatment: case 1. Hepatitis following treatment with gefitinib. J Clin Oncol 2005; 23(33): 8531–8533.

51. Ridruejo E, Cacchione R, Villamil AG et al. Imatinib-induced fatal acute liver failure. World J Gastroenterol 2007; 13(48): 6608–6611.

52. Schiff ER, Mindikoglu AL, Regev A et al. Imatinib mesylate (gleevec) hepatotoxicity. Dig Dis Sci 2007; 52(2): 598–601.

53. Keisner SV, Shah SR. Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma. Drugs 2011; 71(4): 443–454.

54. Hutson TE, Davis ID, Machiels JP et al. Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol 2010; 28(3): 475–480.

55. SPC Nexavar. Dostupné na: http://www.ema.europa.eu/.